JAK2 and myeloproliferative neoplasm: Beyond the characteristic alterations of peripheral blood counts and bone marrow architecture, the JAK2, CALR, and MPL driver mutations have become biomarkers for the diagnosis of MPN and have been incorporated into the WHO classification of hematopoietic malignancies [46].